The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling

Most patients with multiple myeloma treated with current therapies, including immunomodulatory drugs, eventually develop relapsed/refractory disease. Clinical activity of lenalidomide relies on degradation of Ikaros and the consequent reduction in IRF4 expression, both required for myeloma cell surv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Díaz, Tania, Rodríguez, Vanina, Lozano, Ester, Mena, Mari-Pau, Calderón, Marcos, Rosiñol, Laura, Martínez, Antonio, Tovar, Natalia, Pérez-Galán, Patricia, Bladé, Joan, Roué, Gaël, de Larrea, Carlos Fernández
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5622862/
https://ncbi.nlm.nih.gov/pubmed/28751557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.164632
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados